These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 22739667

  • 1. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
    López RL, del Muro XG.
    Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
    [Abstract] [Full Text] [Related]

  • 2. Tumor rupture exposes the patient to an increased risk of relapse, regardless of the size and number of mitoses.
    Quintero CB, Cubedo R.
    Anticancer Drugs; 2012 Jun; 23 Suppl():S1-2. PubMed ID: 22739664
    [No Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
    Majer IM, Gelderblom H, van den Hout WB, Gray E, Verheggen BG.
    J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
    [Abstract] [Full Text] [Related]

  • 4. New fronts in the adjuvant treatment of GIST.
    Reichardt P, Joensuu H, Blay JY.
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):715-23. PubMed ID: 23934322
    [Abstract] [Full Text] [Related]

  • 5. Adjuvant imatinib therapy for gastrointestinal stromal tumors.
    Pisters PW, Colombo C.
    J Surg Oncol; 2011 Dec; 104(8):896-900. PubMed ID: 22069174
    [Abstract] [Full Text] [Related]

  • 6. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
    Kang YK, Kang BW, Im SA, Lee JL, Park SR, Kang WK, Chang HM, Kim TW, Oh DY, Jung KH, Ryu MH.
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
    [Abstract] [Full Text] [Related]

  • 7. Recurrence risk after resection of gastrointestinal stromal tumors: size is not all that matters... The consequences of tumor rupture.
    Han D, Deneve J, Gonzalez RJ.
    Am Surg; 2012 Jan; 78(1):74-9. PubMed ID: 22273319
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
    Jiang WZ, Guan GX, Lu HS, Yang YH, Kang DY, Huang HG.
    J Surg Oncol; 2011 Dec; 104(7):760-4. PubMed ID: 21713778
    [Abstract] [Full Text] [Related]

  • 9. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
    Tielen R, Verhoef C, van Coevorden F, Gelderblom H, Sleijfer S, Hartgrink HH, Bonenkamp JJ, van der Graaf WT, de Wilt JH.
    Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
    [Abstract] [Full Text] [Related]

  • 10. [Imatinib in the GIST therapy: ten years later].
    Lopez M.
    Clin Ter; 2011 Feb; 162(6):563-73. PubMed ID: 22262331
    [Abstract] [Full Text] [Related]

  • 11. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P.
    JAMA; 2012 Mar 28; 307(12):1265-72. PubMed ID: 22453568
    [Abstract] [Full Text] [Related]

  • 12. Adjuvant imatinib for gastrointestinal stromal tumors: the current situation and problems.
    Zhong JH, Ma L, Li LQ, Ru HM, Zhao YN.
    Scand J Gastroenterol; 2011 Jun 28; 46(6):645-51. PubMed ID: 21271901
    [Abstract] [Full Text] [Related]

  • 13. Patient with high-risk GIST not associated with c-KIT mutations: same benefit from adjuvant therapy?
    Izquierdo ME, Bonastre MT.
    Anticancer Drugs; 2012 Jun 28; 23 Suppl():S7-9. PubMed ID: 22739668
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
    Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW.
    Ann Surg Oncol; 2007 Jan 28; 14(1):14-24. PubMed ID: 17072676
    [Abstract] [Full Text] [Related]

  • 19. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
    Li J, Dang YZ, Gao J, Shen L.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar 28; 16(3):216-20. PubMed ID: 23536338
    [Abstract] [Full Text] [Related]

  • 20. Gastrointestinal stromal tumours.
    Connolly EM, Gaffney E, Reynolds JV.
    Br J Surg; 2003 Oct 28; 90(10):1178-86. PubMed ID: 14515284
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.